Unknown

Dataset Information

Predictive effect of molecular and clinical characteristics for the OS and PFS efficacy of anti-PD-1/PD-L1 immunotherapy in patients with NSCLC: a meta-analysis and systematic review


ABSTRACT:

Objective

To evaluate the predictive effect of molecular and clinical characteristics for the efficacy of anti-programmed cell death 1 (PD-1)/programmed cell death ligand-1 (PD-L1) immunotherapy in patients with non-small cell lung cancer (NSCLC).

Design

Systematic review and meta-analysis.

Setting

Twelve randomised controlled trials (RCTs) with 7442 patients were retrieved from all over the world.

Methods

Electronic databases were searched for eligible RCTs. The HRs and 95% CIs for overall survival (OS) and progression‐free survival (PFS) for the whole and subgroup population were extracted for meta-analysis using Review Manager V.5.3 software.

Primary and secondary outcome measure

OS was the primary outcome and PFS was the secondary outcome. <

SUBMITTER: An R 

PROVIDER: S-EPMC8719178 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature